MCF7/TAMR-4 Cell Line
- Name Anne Lykkesfeldt
- Institute Danish Cancer Society
Tool name: MCF7/TAMR-4 Cell Line
Tool type: Cell Lines
Tool sub-type: Continuous
Parental cell line: MCF7 S0.5
Cancer type: Breast cancer, tamoxifen-resistant
Description: The MCF7/TAMR-4 Cell line is a breast cancer cell line resistant to tamoxifen. Tamoxifen is by far the most widely used drug for hormone-dependent breast cancer. However, primary or acquired resistance to Tamoxifen severely limits its clinical effectiveness. The MCF7/TAMR-4 cell line is a good model cell to study the signalling pathways which are the major drivers of tamoxifen-resistant growth.
Research area: Cancer ; Drug Discovery & Development
- For Research Use Only
- • Joshi et al. 2016. Oncotarget. :. PMID: 27528030.
- • Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
- • Elias et al. 2015. Oncogene. 34(15):1919-27. PMID: 24882577.
- • Thrane et al. 2014. Oncogene. PMID: 25362855.
- • A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
- • Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
- • Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
- • Estrogen receptor a is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.
- • Cutrupi et al. 2012. Oncogene. 31(40):4353-61. PMID: 22249258.
- • Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
- • Millour et al. 2010. Oncogene. 29(20):2983-95. PMID: 20208560.
- • FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
- • Pancholi et al. 2008. Endocr Relat Cancer. 15(4):985-1002. PMID: 18824559.
- • ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
- • Sarwar et al. 2006. Endocr Relat Cancer. 13(3):851-61. PMID: 16954434.
- • Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression.